The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
Simon J Harrison, Hang Quach, Emma Link, Huaibao Feng, Joanne Dean, Michael Copeman, Helgi Van de Velde, Anthony Schwarer, Bartrum Baker, Andrew Spencer, John Catalano, Philip Campbell, Bradley Augustson, Ken Romeril, Henry Miles Prince
American Journal of Hematology | WILEY | Published : 2015
S.J.H. and H.M.P. received research funding and participated in advisory boards for Janssen-Cilag. H.F. and H.V.D.V. are employees of Janssen-Cilag. M.C. is a consultant to Janssen-Cilag received honoraria and participated in advisory boards. P.C. has received research funding from Janssen-Cilag. K.R. has participated in advisory boards.